{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T22:07:29Z","timestamp":1790892449154,"version":"4.1.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"S1","license":[{"start":{"date-parts":[[2014,4,1]],"date-time":"2014-04-01T00:00:00Z","timestamp":1396310400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BioDrugs"],"published-print":{"date-parts":[[2014,4]]},"DOI":"10.1007\/s40259-013-0064-z","type":"journal-article","created":{"date-parts":[[2014,3,31]],"date-time":"2014-03-31T14:56:36Z","timestamp":1396277796000},"page":"15-23","source":"Crossref","is-referenced-by-count":112,"title":["Pegylation of Biological Molecules and Potential Benefits: Pharmacological Properties of Certolizumab Pegol"],"prefix":"10.1007","volume":"28","author":[{"given":"Gianfranco","family":"Pasut","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,4,1]]},"reference":[{"issue":"2","key":"64_CR1","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.jconrel.2011.10.037","volume":"161","author":"G Pasut","year":"2012","unstructured":"Pasut G, Veronese FM. State of the art in PEGylation: the great versatility achieved after forty years of research. J Control Release. 2012;161(2):461\u201372.","journal-title":"J Control Release"},{"issue":"3","key":"64_CR2","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1021\/bc050322y","volume":"17","author":"A Basu","year":"2006","unstructured":"Basu A, Yang K, Wang M, Liu S, Chintala R, Palm T, et al. Structure-function engineering of interferon-beta-1b for improving stability, solubility, potency, immunogenicity, and pharmacokinetic properties by site-selective mono-PEGylation. Bioconjug Chem. 2006;17(3):618\u201330.","journal-title":"Bioconjug Chem"},{"issue":"4","key":"64_CR3","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/S0169-409X(02)00026-1","volume":"54","author":"AP Chapman","year":"2002","unstructured":"Chapman AP. PEGylated antibodies and antibody fragments for improved therapy: a review. Adv Drug Deliv Rev. 2002;54(4):531\u201345.","journal-title":"Adv Drug Deliv Rev"},{"issue":"3","key":"64_CR4","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1021\/bc049781+","volume":"16","author":"C Dhalluin","year":"2005","unstructured":"Dhalluin C, Ross A, Leuthold LA, Foser S, Gsell B, Muller F, et al. Structural and biophysical characterization of the 40\u00a0kDa PEG-interferon-alpha2a and its individual positional isomers. Bioconjug Chem. 2005;16(3):504\u201317.","journal-title":"Bioconjug Chem"},{"issue":"9","key":"64_CR5","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1358\/dot.2009.45.9.1416421","volume":"45","author":"G Pasut","year":"2009","unstructured":"Pasut G, Veronese FM. PEGylation for improving the effectiveness of therapeutic biomolecules. Drugs Today (Barc). 2009;45(9):687\u201395.","journal-title":"Drugs Today (Barc)"},{"issue":"5","key":"64_CR6","doi-asserted-by":"crossref","first-page":"315","DOI":"10.2165\/00063030-200822050-00004","volume":"22","author":"FM Veronese","year":"2008","unstructured":"Veronese FM, Mero A. The impact of PEGylation on biological therapies. BioDrugs. 2008;22(5):315\u201329.","journal-title":"BioDrugs"},{"issue":"10","key":"64_CR7","doi-asserted-by":"crossref","first-page":"4167","DOI":"10.1002\/jps.21278","volume":"97","author":"CS Fishburn","year":"2008","unstructured":"Fishburn CS. The pharmacology of PEGylation: balancing PD with PK to generate novel therapeutics. J Pharm Sci. 2008;97(10):4167\u201383.","journal-title":"J Pharm Sci"},{"issue":"12","key":"64_CR8","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1021\/bc800281s","volume":"19","author":"G Pasut","year":"2008","unstructured":"Pasut G, Mero A, Caboi F, Scaramuzza S, Sollai L, Veronese FM. A new PEG-beta-alanine active derivative for releasable protein conjugation. Bioconjug Chem. 2008;19(12):2427\u201331.","journal-title":"Bioconjug Chem"},{"issue":"1","key":"64_CR9","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1002\/cncr.22739","volume":"110","author":"JK Armstrong","year":"2007","unstructured":"Armstrong JK, Hempel G, Koling S, Chan LS, Fisher T, Meiselman HJ, et al. Antibody against poly(ethylene glycol) adversely affects PEG-asparaginase therapy in acute lymphoblastic leukemia patients. Cancer. 2007;110(1):103\u201311.","journal-title":"Cancer"},{"issue":"3","key":"64_CR10","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1002\/art.22403","volume":"56","author":"JS Sundy","year":"2007","unstructured":"Sundy JS, Ganson NJ, Kelly SJ, Scarlett EL, Rehrig CD, Huang W, et al. Pharmacokinetics and pharmacodynamics of intravenous PEGylated recombinant mammalian urate oxidase in patients with refractory gout. Arthritis Rheum. 2007;56(3):1021\u20138.","journal-title":"Arthritis Rheum"},{"issue":"7","key":"64_CR11","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1007\/s11095-013-1067-7","volume":"30","author":"H Schellekens","year":"2013","unstructured":"Schellekens H, Hennink WE, Brinks V. The immunogenicity of polyethylene glycol: facts and fiction. Pharm Res. 2013;30(7):1729\u201334.","journal-title":"Pharm Res"},{"issue":"1\u20132","key":"64_CR12","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ijpharm.2012.04.049","volume":"432","author":"H Koide","year":"2012","unstructured":"Koide H, Asai T, Kato H, Ando H, Shiraishi K, Yokoyama M, et al. Size-dependent induction of accelerated blood clearance phenomenon by repeated injections of polymeric micelles. Int J Pharm. 2012;432(1\u20132):75\u20139.","journal-title":"Int J Pharm"},{"issue":"6","key":"64_CR13","doi-asserted-by":"crossref","first-page":"e39659","DOI":"10.1371\/journal.pone.0039659","volume":"7","author":"C Zhang","year":"2012","unstructured":"Zhang C, Fan K, Ma X, Wei D. Impact of large aggregated uricases and PEG diol on accelerated blood clearance of PEGylated canine uricase. PLoS One. 2012;7(6):e39659.","journal-title":"PLoS One"},{"issue":"10","key":"64_CR14","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1111\/j.1365-2893.2012.01598.x","volume":"19","author":"F Matsuda","year":"2012","unstructured":"Matsuda F, Torii Y, Enomoto H, Kuga C, Aizawa N, Iwata Y, et al. Anti-interferon-alpha neutralizing antibody is associated with nonresponse to pegylated interferon-alpha plus ribavirin in chronic hepatitis C. J Viral Hepat. 2012;19(10):694\u2013703.","journal-title":"J Viral Hepat"},{"issue":"7","key":"64_CR15","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.3899\/jrheum.111375","volume":"39","author":"V Strand","year":"2012","unstructured":"Strand V, Khanna D, Singh JA, Forsythe A, Edwards NL. Improved health-related quality of life and physical function in patients with refractory chronic gout following treatment with pegloticase: evidence from phase III randomized controlled trials. J Rheumatol. 2012;39(7):1450\u20137.","journal-title":"J Rheumatol"},{"issue":"4","key":"64_CR16","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1345\/aph.1D297","volume":"38","author":"EA Bell","year":"2004","unstructured":"Bell EA, Wall GC. Pediatric constipation therapy using guidelines and polyethylene glycol 3350. Ann Pharmacother. 2004;38(4):686\u201393.","journal-title":"Ann Pharmacother"},{"issue":"3","key":"64_CR17","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.jpeds.2003.11.033","volume":"144","author":"DS Pashankar","year":"2004","unstructured":"Pashankar DS, Uc A, Bishop WP. Polyethylene glycol 3350 without electrolytes: a new safe, effective, and palatable bowel preparation for colonoscopy in children. J Pediatr. 2004;144(3):358\u201362.","journal-title":"J Pediatr"},{"issue":"1","key":"64_CR18","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1124\/dmd.106.012419","volume":"35","author":"R Webster","year":"2007","unstructured":"Webster R, Didier E, Harris P, Siegel N, Stadler J, Tilbury L, et al. PEGylated proteins: evaluation of their safety in the absence of definitive metabolism studies. Drug Metab Dispos. 2007;35(1):9\u201316.","journal-title":"Drug Metab Dispos"},{"issue":"4","key":"64_CR19","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1002\/jps.2600830432","volume":"83","author":"T Yamaoka","year":"1994","unstructured":"Yamaoka T, Tabata Y, Ikada Y. Distribution and tissue uptake of poly(ethylene glycol) with different molecular weights after intravenous administration to mice. J Pharm Sci. 1994;83(4):601\u20136.","journal-title":"J Pharm Sci"},{"issue":"8\u20139","key":"64_CR20","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/j.progpolymsci.2007.05.008","volume":"32","author":"G Pasut","year":"2007","unstructured":"Pasut G, Veronese FM. Polymer-drug conjugation, recent achievements and general strategies. Prog Polym Sci. 2007;32(8\u20139):933\u201361.","journal-title":"Prog Polym Sci"},{"issue":"2","key":"64_CR21","doi-asserted-by":"crossref","first-page":"137","DOI":"10.4161\/mabs.2.2.11271","volume":"2","author":"N Goel","year":"2010","unstructured":"Goel N, Stephens S. Certolizumab pegol. MAbs. 2010;2(2):137\u201347.","journal-title":"MAbs."},{"issue":"4","key":"64_CR22","first-page":"535","volume":"3","author":"N Weir","year":"2006","unstructured":"Weir N, Athwal D, Brown D, Foulkes R, Kollias G, Nesbitt A, et al. A new generation of high-affinity humanized PEGylated Fab\u2019 fragment anti-tumor necrosis factor-alpha monoclonal antibodies. Therapy. 2006;3(4):535\u201345.","journal-title":"Therapy"},{"issue":"2","key":"64_CR23","doi-asserted-by":"crossref","first-page":"93","DOI":"10.2165\/00063030-200923020-00003","volume":"23","author":"RE Kontermann","year":"2009","unstructured":"Kontermann RE. Strategies to extend plasma half-lives of recombinant antibodies. BioDrugs. 2009;23(2):93\u2013109.","journal-title":"BioDrugs"},{"issue":"4 Suppl. 2","key":"64_CR24","first-page":"A697","volume":"130","author":"A Gramlick","year":"2006","unstructured":"Gramlick A, Fossati G, Nesbitt AM. Neutralization of soluble and membrane tumor necrosis factor-\u03b1 (TNF-\u03b1) by infliximab, adalimumab, or certolizumab pegol using P55 or P75 TNF-\u03b1 receptor-specific bioassays. Gastroenterology. 2006;130(4 Suppl. 2):A697.","journal-title":"Gastroenterology"},{"issue":"11","key":"64_CR25","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1002\/ibd.20225","volume":"13","author":"A Nesbitt","year":"2007","unstructured":"Nesbitt A, Fossati G, Bergin M, Stephens P, Stephens S, Foulkes R, et al. Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor alpha agents. Inflamm Bowel Dis. 2007;13(11):1323\u201332.","journal-title":"Inflamm Bowel Dis"},{"key":"64_CR01","author":"P-L Meroni","year":"2013","unstructured":"Meroni P-L, Valensini G. Tumour necrosis factor \u03b1 antagonists in the treatment of rheumatoid arthritis: an immunological perspective. BioDrugs. 2013. doi: 10.1007\/s40259-013-0063-0 .","journal-title":"BioDrugs"},{"issue":"5","key":"64_CR26","doi-asserted-by":"crossref","first-page":"331","DOI":"10.2165\/00063030-200822050-00005","volume":"22","author":"T Bourne","year":"2008","unstructured":"Bourne T, Fossati G, Nesbitt A. A PEGylated Fab\u2019 fragment against tumor necrosis factor for the treatment of Crohn disease: exploring a new mechanism of action. BioDrugs. 2008;22(5):331\u20137.","journal-title":"BioDrugs"},{"issue":"Suppl. 10","key":"64_CR27","first-page":"718","volume":"62","author":"D Wolf","year":"2010","unstructured":"Wolf D, Mahadevan U. Certolizumab pegol use in pregnancy: low levels detected in cord blood [abstract]. Arthritis Rheum. 2010;62(Suppl. 10):718.","journal-title":"Arthritis Rheum"},{"issue":"5 Suppl. 1","key":"64_CR28","doi-asserted-by":"crossref","first-page":"S61","DOI":"10.1016\/S0016-5085(11)60251-5","volume":"140","author":"U Mahadevan","year":"2011","unstructured":"Mahadevan U, Miller JK, Wolf DC. Adalimumab levels detected in cord blood and infants exposed in utero [abstract no. 277]. Gastroenterology. 2011;140(5 Suppl. 1):S61\u20132.","journal-title":"Gastroenterology"},{"issue":"4 Suppl. 1","key":"64_CR29","first-page":"A144","volume":"132","author":"U Mahadevan","year":"2007","unstructured":"Mahadevan U, Terdiman JP, Church J, Vasiliauskas E, Gitis A, Dubinsky MC. Infliximab levels in infants born to women with inflammatory bowel disease [abstract no. 959]. Gastroenterology. 2007;132(4 Suppl. 1):A144.","journal-title":"Gastroenterology"},{"issue":"Suppl. 6","key":"64_CR30","first-page":"A47","volume":"53","author":"AM Nesbitt","year":"2004","unstructured":"Nesbitt AM, Henry AJ. High affinity and potency of the PEGylated Fab\u2019 fragment CDP870\u2014a direct comparison with other anti-TNF agents [abstract]. Gut. 2004;53(Suppl. 6):A47.","journal-title":"Gut"},{"key":"64_CR31","doi-asserted-by":"crossref","unstructured":"Lamour S, Bracher M, Nesbitt A. Effect of the peg component of certolizumab pegol on stimulated mast cell degranulation [abstract]. Gut. 2009;58(Suppl. III):A305.","DOI":"10.1097\/00054725-200912002-00080"},{"issue":"3","key":"64_CR32","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1038\/nrrheum.2013.4","volume":"9","author":"PA Schouwenburg van","year":"2013","unstructured":"van Schouwenburg PA, Rispens T, Wolbink GJ. Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis. Nat Rev Rheumatol. 2013;9(3):164\u201372.","journal-title":"Nat Rev Rheumatol"},{"issue":"12","key":"64_CR33","doi-asserted-by":"crossref","first-page":"3782","DOI":"10.1002\/art.22214","volume":"54","author":"K Bendtzen","year":"2006","unstructured":"Bendtzen K, Geborek P, Svenson M, Larsson L, Kapetanovic MC, Saxne T. Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab. Arthritis Rheum. 2006;54(12):3782\u20139.","journal-title":"Arthritis Rheum"},{"key":"64_CR34","doi-asserted-by":"crossref","unstructured":"Garces S, Demengeot J, Benito-Garcia E. The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: a systematic review of the literature with a meta-analysis. Ann Rheum Dis. Epub 2012 Dec 6.","DOI":"10.1136\/annrheumdis-2012-eular.3425"},{"issue":"2","key":"64_CR35","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1136\/annrheumdis-2012-202545","volume":"72","author":"FB Vincent","year":"2013","unstructured":"Vincent FB, Morand EF, Murphy K, Mackay F, Mariette X, Marcelli C. Antidrug antibodies (ADAb) to tumour necrosis factor (TNF)-specific neutralising agents in chronic inflammatory diseases: a real issue, a clinical perspective. Ann Rheum Dis. 2013;72(2):165\u201378.","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"64_CR36","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1136\/annrheumdis-2012-201544","volume":"71","author":"CL Krieckaert","year":"2012","unstructured":"Krieckaert CL, Nurmohamed MT, Wolbink GJ. Methotrexate reduces immunogenicity in adalimumab treated rheumatoid arthritis patients in a dose dependent manner. Ann Rheum Dis. 2012;71(11):1914\u20135.","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"64_CR37","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1136\/annrheumdis-2011-200828","volume":"71","author":"C Plasencia","year":"2012","unstructured":"Plasencia C, Pascual-Salcedo D, Nuno L, Bonilla G, Villalba A, Peiteado D, et al. Influence of immunogenicity on the efficacy of longterm treatment of spondyloarthritis with infliximab. Ann Rheum Dis. 2012;71(12):1955\u201360.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"64_CR38","doi-asserted-by":"crossref","first-page":"3","DOI":"10.2147\/nano.2007.2.1.3","volume":"2","author":"T Barnes","year":"2007","unstructured":"Barnes T, Moots R. Targeting nanomedicines in the treatment of rheumatoid arthritis: focus on certolizumab pegol. Int J Nanomed. 2007;2(1):3\u20137.","journal-title":"Int J Nanomed"},{"key":"64_CR39","unstructured":"Vetterlein O, Kopotsha T, Nesbitt A, Brown D, Stephens S. In patients with rheumatoid arthritis treated with the anti-TNF certolizumab pegol or infliximab, antibodies produced do not cross react with other reagents [poster no. THU0121]. European League Against Rheumatism (EULAR); 13\u201316 Jun 2007; Barcelona."},{"issue":"4","key":"64_CR40","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/clpt.2009.136","volume":"86","author":"BD Lacroix","year":"2009","unstructured":"Lacroix BD, Lovern MR, Stockis A, Sargentini-Maier ML, Karlsson MO, Friberg LE. A pharmacodynamic Markov mixed-effects model for determining the effect of exposure to certolizumab pegol on the ACR20 score in patients with rheumatoid arthritis. Clin Pharmacol Ther. 2009;86(4):387\u201395.","journal-title":"Clin Pharmacol Ther"},{"key":"64_CR48","doi-asserted-by":"crossref","unstructured":"Punzi L, Lapadula G, Mathieu A. Efficacy and safety of certolizumab pegol in rheumatoid arthritis: meeting rheumatologists\u2019 requirements in routine clinical practice. BioDrugs. 2013. doi: 10.1007\/s40259-013-0065-y","DOI":"10.1007\/s40259-013-0065-y"},{"key":"64_CR41","unstructured":"UCB Inc. Cimzia (certolizumab pegol) prescribing information. Smyrna (GA): UBC, Inc.; 2011. http:\/\/www.cimzia.com\/pdf\/Prescribing_Information.pdf . Accessed 30 May 2013."},{"issue":"Suppl. 3","key":"64_CR42","first-page":"189","volume":"68","author":"A Parton","year":"2009","unstructured":"Parton A, King L, Parker G, Nesbitt A. The PEG moiety of certolizumab pegol is rapidly cleared from the blood of humans by the kidneys once it is cleaved from the Fab\u2019 [abstract no. THU0051]. Ann Rheum Dis. 2009;68(Suppl. 3):189.","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"64_CR43","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1093\/rheumatology\/41.10.1133","volume":"41","author":"EH Choy","year":"2002","unstructured":"Choy EH, Hazleman B, Smith M, Moss K, Lisi L, Scott DG, et al. Efficacy of a novel PEGylated humanized anti-TNF fragment (CDP870) in patients with rheumatoid arthritis: a phase II double-blinded, randomized, dose-escalating trial. Rheumatology. 2002;41(10):1133\u20137.","journal-title":"Rheumatology"},{"issue":"1\u20132","key":"64_CR44","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.jim.2009.06.009","volume":"348","author":"R Palframan","year":"2009","unstructured":"Palframan R, Airey M, Moore A, Vugler A, Nesbitt A. Use of biofluorescence imaging to compare the distribution of certolizumab pegol, adalimumab, and infliximab in the inflamed paws of mice with collagen-induced arthritis. J Immunol Methods. 2009;348(1\u20132):36\u201341.","journal-title":"J Immunol Methods"},{"issue":"7","key":"64_CR45","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1002\/eji.1830260718","volume":"26","author":"NE Simister","year":"1996","unstructured":"Simister NE, Story CM, Chen HL, Hunt JS. An IgG-transporting Fc receptor expressed in the syncytiotrophoblast of human placenta. Eur J Immunol. 1996;26(7):1527\u201331.","journal-title":"Eur J Immunol"},{"issue":"Suppl. 2","key":"64_CR46","doi-asserted-by":"crossref","first-page":"S438","DOI":"10.14309\/00000434-200609001-01119","volume":"101","author":"AM Nesbitt","year":"2006","unstructured":"Nesbitt AM, Brown DT, Stephens S, Foulkes R. Placental transfer and accumulation in milk of the anti-TNF antibody TN3 in rats: immunoglobulin G1 versus PEGylated Fab\u2019 [abstract]. Am J Gastroenterol. 2006;101(Suppl. 2):S438.","journal-title":"Am J Gastroenterol"},{"key":"64_CR47","unstructured":"Immunex Corporation. Enbrel (etanercept) prescribing information. 2011. http:\/\/pi.amgen.com\/united_states\/enbrel\/derm\/enbrel_pi.pdf . Accessed 30 May 2013."}],"container-title":["BioDrugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-013-0064-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40259-013-0064-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-013-0064-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,17]],"date-time":"2020-08-17T01:53:13Z","timestamp":1597629193000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40259-013-0064-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,4]]},"references-count":49,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[2014,4]]}},"alternative-id":["64"],"URL":"https:\/\/doi.org\/10.1007\/s40259-013-0064-z","relation":{},"ISSN":["1173-8804","1179-190X"],"issn-type":[{"value":"1173-8804","type":"print"},{"value":"1179-190X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,4]]}}}